AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 210.22B +29.9% |
| Revenue (ttm) | 45.77B +9.9% |
| Net Income | 7.87B +33.7% |
| EPS | 5.03 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 26.95 |
| Forward PE | 17.13 |
| Dividend | 2.36 (1.74%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 1,513,279 |
| Open | 13,592 |
| Previous Close | 13,554 |
| Day's Range | 13,588 - 13,864 |
| 52-Week Range | 101 - 13,864 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 16,475.14 (+18.89%) |
| Earnings Date | Jul 27, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 16,475p, which is an increase of 18.89% from the latest price.
News
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, June 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NY...
AstraZeneca PLC (AZN) Shares Surge 3.1% -- What GF Score of 83 Tells Investors
AstraZeneca PLC (AZN) Shares Surge 3.1% -- What GF Score of 83 Tells Investors
AstraZeneca (AZN) Engages with FDA Leadership on Rare Disease Initiatives
AstraZeneca (AZN) Engages with FDA Leadership on Rare Disease Initiatives
FTSE 100 drops amid China banking concerns and falling oil prices
The UK's benchmark FTSE 100 index fell to its lowest level in more than two weeks on Thursday, weighed down by sharp declines in Asia-focused lenders and miners after reports of tighter offshore banki...
AstraZeneca CEO: AI is affecting every part of our company
AstraZeneca CEO Pascal Soriot joins CNBC’s Angelica Peebles to discuss the most promising drugs in AstraZeneca’s pipeline. He says the future is about innovating into new indications with the drugs an...
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment For Ampligen In Pancreatic Cancer; Stock Down
(RTTNews) - AIM ImmunoTech Inc. (AIM), an immune pharma company, announced the final enrolment of subjects in the Phase 2 clinical trial dubbed DURIPANC, evaluating AIM's drug Ampligen (rintatolimod) ...
AstraZeneca (AZN) Benefits from New FDA Guidance on Gene Therapy Development
AstraZeneca (AZN) Benefits from New FDA Guidance on Gene Therapy Development
AstraZeneca's Camizestrant Shows Strong Results in Phase III Trial (AZN)
AstraZeneca's Camizestrant Shows Strong Results in Phase III Trial (AZN)
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant
AstraZeneca announces additional results from Phase III Serena-6 trial
Further positive results from the Phase III Serena-6 trial showed AstraZeneca’s (AZN) camizestrant plus a cyclin-dependent kinase, CDK, 4/6 inhibitor – palbociclib, ribociclib or abemaciclib – maintai...
AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial
Further positive results from the Phase III SERENA-6 trial showed AstraZeneca’s (AZN) camizestrant plus a cyclin-dependent kinase 4/6 inhibitor – palbociclib, ribociclib or abemaciclib – maintained it...
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
WILMINGTON, Del.--(BUSINESS WIRE)--Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor – palbociclib, riboci...
AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100
AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100
5 Foreign Stocks That Could Beat The S&P 500
James Demmert explains why foreign markets are beating the U.S.—and the five international stocks he thinks can outperform the S&P 500.
AstraZeneca (AZN) Reports Positive Results in Phase III Trial for HCC Treatment
AstraZeneca (AZN) Reports Positive Results in Phase III Trial for HCC Treatment
AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi
Positive results from the EMERALD-3 Phase III trial showed AstraZeneca’s (AZN) Imfinzi in combination with Imjudo, lenvatinib and transarterial chemoembolization, TACE, demonstrated a statistically si...
AstraZeneca Scores In Liver Cancer On Its Path To $40 Billion In Oncology Sales
AstraZeneca added to its Imfinzi armamentarium on Monday after the immuno-oncology drug led to improved survival in liver cancer patients.
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transa...
AstraZeneca Transcript: Investor update
Significant pipeline progress includes approvals for new molecular entities and robust phase III momentum. EMERALD-3 demonstrated strong PFS and OS trends in liver cancer, supporting blockbuster potential. Oncology assets, including ADCs and bispecifics, are driving innovation and commercial growth.
AstraZeneca Slides: Investor update
AstraZeneca has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology
LUND, SE / ACCESS Newswire / June 1, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it w...
Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart
NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple the...
Anselamimab Shows Promise in Phase 3 Trials for AL Amyloidosis (AZN)
Anselamimab Shows Promise in Phase 3 Trials for AL Amyloidosis (AZN)
AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint
The company states: “The global CARES Phase 3 clinical programme showed that treatment with anselamimab, a potential first-in-class anti-fibril therapy, resulted in nominally statistically significant...
AstraZeneca (AZN) Gains Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Gains Approval for Imfinzi in Bladder Cancer Treatment